Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions

Clear-Cell Renal Cell Carcinoma

Interventions

DRUG

Sitravatinib

Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

DRUG

Nivolumab

Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

DRUG

Ipilimumab

Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody

Trial Locations (1)

MD Anderson, Houston